Concenter BioPharma
FOCUSED ON PEOPLE AND THERAPIES

Developing Novel Drugs for Treating and Preventing Type 2 Diabetes

Investment Summary:

Fundraising goal: $2.5 M

- Clinical Trials in Israel (Phase 2a) and India (Phase 2 pre-licensure study)
- Completing the laboratory studies requested by FDA and re-submission of the updated IND package
- India market launch approval after Phase 2 due to unmet medical need status

Use of Funds:

Drug Manufacturing - **$500K**
Clinical Trials - **$450K**
Laboratory research - **$1,030K**
Salaries – **$380K**

Business Summary:

Completing requirements of CDSCO (Indian equivalent of the US FDA) to enter the Indian market.
Out-license Zygosid-50 drug to a global pharmaceutical company for finalizing the clinical trials (Phase 2b/3), manufacturing and commercialization. The licensing partner will capture the US market followed by the EU markets and then expand to the rest of the world, paying the royalties.

Contact:

Mr. Dror Chevion **+972-54-5767-050**
dror@concenterbiopharma.com

Biotechnology/Pharmaceuticals Sub-category:
Drug development: Small Molecules

Problem and Market:

Problem

Existing T2D medications target symptoms and complications of the disease or impact the lifestyle without affecting the core of T2D – Insulin Resistance.

Solution

Zygosid-50, the novel oral drug, prevents and treats T2D, stabilizes weight without changing a diet or a lifestyle, targeting the core pathophysiologic defect of T2D: elevated and continuously rising Insulin Resistance.

T2D Market

- T2D is a Global Epidemic; Worldwide - over 537M patients in 2021, expected to reach 783 M by 2045 (IDF Diabetes Atlas 2021);
- USA - over 32M patients (13.6% of the population); 97M people 18+ (38.0% of the adult populations) have pre-diabetes (National Diabetes Statistics report - CDC);
- US T2D drugs market was $32B in 2022 (Precedence Research);
- EU T2D drugs market is $15.8B in 2023 (Mordor Intelligence);
- India T2D drugs market is $1.7B (Mordor Intelligence);

Technology:

Zygosid-50 first-in-class oral, cost-effective anti-T2D drug with a novel mechanism of action, has proven safe and efficacious for treating of diabetics and prophylaxis in pre-diabetics, producing potent multifactorial effects:

Preclinical model:

- Reduced both blood glucose (from >300 mg/dl to <100 mg/dl) and insulin resistance (>90%) to normal levels - better than any other drug.
- Normalized diabetes-associated derailment of lipid profile
- Suppressed the expression of pro-inflammatory cytokines.
  (Diabetes Metab J. 2024 Jan 3. doi: 10.4093/dmj.2022.0292)

Clinical trial:

- Reduced insulin resistance (>50%, better than any other drug) and increased time-in-range (glucose control efficacy) from 41% to 90%
- No systemic adverse events were observed.

Team:

Dror Chevion, MBA – CEO.
Successful Serial Entrepreneur with over 25 years of global experience in several industries including CEO and Co-Founder in Truly Protect; Executive VP BD in Ness Technologies (conceived and implemented business plan for creating Ness Technologies a global IT solutions provider by merging 5 Israeli IT companies; 2,200 employees; $200 MM revenue).

Itzchak Angel, PhD – Head of Discovery and R&D.
Accomplished executive in the Pharmaceutical Industry with over 35 years' experience in strategic business development; contributed to commercialization of five novel drugs.

Vladimir Vinokur, PhD, MRSB – Head of Biology.
One of Zygosid-50 co-inventors, 15+ years in drugs development, The UK Academy of Medical Sciences Fellowship awardee.

Susan Alpert, MD, PhD – Regulatory Lead.
30+ years in regulatory affairs, Chief Regulatory Officer and SVP of Global Regulatory Affairs at Medtronic Inc., Division Head at FDA

SAB:

Prof. Ralph DeFronzo (USA) - laureate of the highest achievement awards given by the American and European Diabetes Associations, and **Prof. Peter Nawroth** (Germany) - Camillo Golgi prize awardee.